Abstract
Precision oncology has largely been driven by genomic profiling, but success so far has been limited. By combining genomic and proteomic analyses of tumours, proteogenomics holds promise in providing deeper mechanistic insights and generating therapeutic hypotheses to better match patients to targeted treatments than analysing each 'ome in isolation.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Gene Expression Profiling
-
Humans
-
Mass Spectrometry
-
Molecular Targeted Therapy
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / metabolism
-
Precision Medicine
-
Proteogenomics / methods*